Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571714 | PMC |
| http://dx.doi.org/10.3389/fspor.2023.1285884 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel open-source cultivation system helps establish the first full cycle chemosynthetic symbiosis model system involving the giant ciliate .
Front Microbiol
December 2024
Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, United States.
Symbiotic interactions drive species evolution, with nutritional symbioses playing vital roles across ecosystems. Chemosynthetic symbioses are globally distributed and ecologically significant, yet the lack of model systems has hindered research progress. The giant ciliate and its sulfur-oxidizing symbionts represent the only known chemosynthetic symbiosis with a short life span that has been transiently cultivated in the laboratory.
View Article and Find Full Text PDFCardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosis.
Physiol Rep
December 2024
Integrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.
Multiple sclerosis (MS) is a chronic neurological condition resulting in decreased aerobic capacity (peak VO). The hemodynamic responses to peak exercise in MS are unknown. Further, it is unknown if the hemodynamic responses are due to disease or fitness.
View Article and Find Full Text PDFBalancing Tradition and Nutrition: Jamu in Menstrual Cycle-Based Dietary Guidance.
Nutr Rev
December 2024
Guidance and Counseling Department, Universitas Negeri Malang, Malang, East Java, 65145, Indonesia.
Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.
MedComm (2020)
January 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Breast Tumor Centre Phase I Clinical Trial Centre, Clinical Research Design Division, Clinical Research Center Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou Guangdong China.
This multicenter, single-arm, phase II clinical trial (NCT04034589) evaluated the efficacy and safety of pyrotinib combined with fulvestrant in patients with HR-positive/HER2-positive metastatic breast cancer who had experienced trastuzumab treatment failure. A total of 46 patients were enrolled, receiving pyrotinib orally once daily and fulvestrant intramuscularly on days 1 and 15 of cycle 1, followed by monthly doses on day 1. The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!